16 results
8-K
EX-99.1
ONCR
Oncorus, Inc.
26 Jun 23
Hilco Streambank Seeks Offers to Acquire Patent Portfolio of Biopharmaceutical Company Oncorus
4:01pm
delivery system technologies, but also a starting place from which to accelerate costly R&D efforts.” Maersch continued, “Oncorus’ state-of-the-art
10-K
2020 FY
ONCR
Oncorus, Inc.
10 Mar 21
Annual report
4:12pm
and research and development tax credits, or R&D credits, as a result of our incurrence of losses and our conduct of research activities since inception … . As of December 31, 2020, we also had federal and state R&D credit carryforwards of $3.3 million and $1.5 million, respectively. Our federal R&D credit
424B4
ONCR
Oncorus, Inc.
12 Feb 21
Prospectus supplement with pricing info
4:23pm
be limited or restricted.
We have generated significant NOL carryforwards and research and development tax credits, or R&D credits, as a result of our … generated in tax years beginning after December 31, 2020 is limited. As of December 31, 2019, we also had federal and state R&D credit carryforwards
DRS
r41g 8i9ggfhnejwao
28 Jan 21
Draft registration statement
12:00am
DRS
EX-10.21
f6fldmp5u 36z
28 Jan 21
Draft registration statement
12:00am
10-Q
k8x hnujjz
12 Nov 20
Quarterly report
8:01am
424B4
8vxs33naz
2 Oct 20
Prospectus supplement with pricing info
12:00am
S-1
cshcp1xf 4g
11 Sep 20
IPO registration
4:49pm
DRS/A
uqd1av1
26 Aug 20
Draft registration statement (amended)
12:00am
DRS/A
emmb1q55l4 qin
29 Jul 20
Draft registration statement (amended)
12:00am
DRS/A
zb6ykta7om 5bp7r
20 Dec 19
Draft registration statement (amended)
12:00am
DRS
1pkg6let 5kyskfj
31 Oct 19
Draft registration statement
12:00am
- Prev
- 1
- Next